Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...

The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset ...

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.

For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process. In ...

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity ...